Japanese firm Takeda has announced ILLUMINATE - a rare disease diagnosis program to support improved clinical results for patients with Lysosomal Storage Disorders (LSD), independently run and managed by PerkinElmer and sponsored by Baxalta Bioscience India Pvt Ltd (part of Takeda group of companies).

This program will support improved diagnostic pathways for patients with LSDs such as Gaucher disease, Fabry disease, and mucopolysaccharidosis Type II (MPSII; Hunter Syndrome).

In its first phase, the program will be implemented by PerkinElmer at specific centers in Delhi, Haryana, Uttar Pradesh, Madhya Pradesh, Gujarat, Rajasthan, Maharashtra, Kolkata, Tamil Nadu, and Karnataka.

Sumedha Gupta, Head of Patient Services, Takeda India, said, “Over two years – we look at targeting diagnosis for ~10,000 patients through our partner PerkinElmer and subsequently improve the diagnostic rate, which is currently observed as less than 1%.”